Posted 04 April 2016 - 01:18 PM
Posted 04 April 2016 - 01:21 PM
Posted 06 April 2016 - 03:00 AM
I wondered about the whole issue of SIBO testing, since neither gastro doctor I've been to showed any interest in testing for SIBO.
I thought that Xifraxan was explictly approved for treatment of IBS-D. On the other hand, [correct me if I'm wrong] I thought I read an article indicating that there was some evidence that Xifraxan can also be effective in treating IBS-C. So, should people with IBS-C consider asking their doctors for a course of Xifraxan, if they haven't gotten enough relief from diet changes or other treatments?
I find all of this a bit confusing. Xifraxan could be effective for IBS-C, even though it's not approved for that form of IBS. What is the reason that Xifraxan is only approved for IBS-D? Of course, it is fairly common for doctors to engage in off label prescribing (e.g., prescribing a medication for something other than what it was explicitly approved by the FDA for).
This reminds me of how Amitiza is approved for women with IBS-C, but not men with IBS-C, but doctors will prescribe it to men with IBS-C. In that case, the reason it was only approved for women with IBS was because the research study demonstrating its efficacy did not include enough men to make a conclusive judgment of its efficacy in men--from what I understand, the reason for including much fewer men than women in the study was because more women suffer from IBS than men, not because of any indication that Amitiza would be less effective in men. BTW, that seems like a ridiculous reason to include so few men, as IBS isn't exactly a rarity in men; the statistic I saw was that approximately twice as many women suffer from IBS as men. That is a major gender difference, but it's not like breast cancer where 90+% of breast cancer patients are women.